LAG3 and colorectal cancer: Given that two-thirds of the patients included in the cohort of Chen et al. had stage III and IV colorectal cancers, it might not be surprising that high versus low LAG-3+ expression in the mixed stage I–IV cohort was associated with shorter survival.